TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.

[1]  B. Falini,et al.  CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. , 2010, Blood.

[2]  Pu Zhang,et al.  PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2 , 2010, Nature Medicine.

[3]  J. Gribben,et al.  Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. , 2010, Blood.

[4]  O. Ohara,et al.  Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells , 2010, Science Translational Medicine.

[5]  K. Akashi,et al.  FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. , 2009, Blood.

[6]  I. Weissman,et al.  CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis , 2009, Cell.

[7]  Ash A. Alizadeh,et al.  CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.

[8]  J. Dick,et al.  Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. , 2009, Cell stem cell.

[9]  K. Takeda,et al.  Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. , 2009, Blood.

[10]  D. Greiner,et al.  Non‐obese diabetic–recombination activating gene‐1 (NOD–Rag 1 null) interleukin (IL)‐2 receptor common gamma chain (IL 2 rγnull) null mice: a radioresistant model for human lymphohaematopoietic engraftment , 2008, Clinical and experimental immunology.

[11]  J. Gribben,et al.  Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. , 2008, Blood.

[12]  K. Akashi,et al.  Differential Effects of the Type I Interferons α4, β, and ε on Antiviral Activity and Vaccine Efficacy1 , 2008, The Journal of Immunology.

[13]  I. Ishida,et al.  Complement Activation Plays a Key Role in Antibody-Induced Infusion Toxicity in Monkeys and Rats , 2008, The Journal of Immunology.

[14]  J. Dick,et al.  Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells , 2007, Nature Immunology.

[15]  David E. Anderson,et al.  Promotion of Tissue Inflammation by the Immune Receptor Tim-3 Expressed on Innate Immune Cells , 2007, Science.

[16]  R. V. van Etten,et al.  Right on target: eradicating leukemic stem cells. , 2007, Trends in molecular medicine.

[17]  Satoshi Tanaka,et al.  Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region , 2007, Nature Biotechnology.

[18]  S. Nakae,et al.  TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells. , 2007, Blood.

[19]  I. Weissman,et al.  CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia , 2007, Proceedings of the National Academy of Sciences.

[20]  J. Ravetch,et al.  Antibodies, Fc receptors and cancer. , 2007, Current opinion in immunology.

[21]  D. Printz,et al.  Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells , 2007, European journal of clinical investigation.

[22]  L. Yalcintepe,et al.  Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. , 2006, Blood.

[23]  J. Dick,et al.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.

[24]  P. Valent,et al.  Detection of molecular targets on the surface of CD34+/CD38− stem cells in various myeloid malignancies , 2006, Leukemia & lymphoma.

[25]  T. Lister,et al.  Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. , 2005, Blood.

[26]  J. Ravetch,et al.  Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding , 2005, Science.

[27]  G. V. van Dongen,et al.  The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. , 2005, Blood.

[28]  K. Akashi,et al.  Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice , 2005 .

[29]  J. Dick,et al.  Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity , 2004, Nature Immunology.

[30]  K. Haas,et al.  The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy , 2004, The Journal of experimental medicine.

[31]  V. Kuchroo,et al.  Tim-3 inhibits T helper type 1–mediated auto- and alloimmune responses and promotes immunological tolerance , 2003, Nature Immunology.

[32]  G. Freeman,et al.  Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance , 2003, Nature Immunology.

[33]  Irving L. Weissman,et al.  Prospective isolation of human clonogenic common myeloid progenitors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Tatyana Chernova,et al.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease , 2002, Nature.

[35]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[36]  M. Hallek,et al.  Rapid amplification of cDNA ends (RACE) improves the PCR-based isolation of immunoglobulin variable region genes from murine and human lymphoma cells and cell lines , 1997, Leukemia.

[37]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[38]  J. Dick,et al.  Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[40]  M. Miyasaka,et al.  Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice , 1993, The Journal of experimental medicine.